Nux Vomica Extract

Summary

Nux Vomica Extract (CHEMBL2107927) is a phase-3 clinical-stage unknown; indicated across 1 condition including premenstrual tension.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107927
Name	Nux Vomica Extract
Type	Unknown
Max phase	3

Also known as: Ma qian zi seed, Maqianzi, Nux vomica, Nux vomica extract, Poison-nut tree seed, Strychni semen, Strychnine tree seed, Strychnos nux-vomica seed, Strychnos nux-vomica seed extract, Strychnos spireana seed, Vishamushti seed, Vishatinduka seed

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
premenstrual tension	3	MONDO:0004169	MONDO:0004169

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02402049	PHASE3	UNKNOWN	Homeopathic Treatment of Premenstrual Syndrome
NCT00895453	Not specified	COMPLETED	Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).